Comparison of Real-World Outcomes of 2nd Targeted Therapies in Patients with Metastatic Renal Cell Carcinoma (mRCC) – a Multi-Country Retrospective Chart Review
Recruiting
- Conditions
- Oncology- Metastatic renal cell carcinoma (mRCC)
- Registration Number
- NL-OMON23232
- Lead Sponsor
- ovartis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 450
Inclusion Criteria
• Adult patients (age ≥18 years, males and females) diagnosed with mRCC per medical chart
Exclusion Criteria
• The patient used an mTOR inhibitor, bevacizumab or cytokines [IL-2, IFN- α2a] prior to initiation of the 2nd targeted therapy
• The patient used a combination therapy with ≥2 targeted agents prior to or upon the initiation of the 2nd targeted therapy
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Characterize differences in the following outcomes in mRCC patients receiving 2nd targeted therapy with everolimus, sorafenib, or axitinib following a 1st targeted therapy with sunitinib or pazopanib:<br><br /><br /><br>a. OS from the initiation of 2nd targeted therapy<br /><br>b. Treatment duration of the 2nd targeted therapy<br /><br>c. PFS from the initiation of 2nd targeted therapy
- Secondary Outcome Measures
Name Time Method Characterize differences in the primary outcomes within subgroups stratified by the following groups:<br /><br>a. Type of 1st targeted therapy used<br /><br>b. Long/short duration of 1st targeted therapy<br /><br /><br><br>Describe real-world treatment patterns:<br /><br>a. Treatment duration of targeted therapies (by lines of treatment), and reasons for discontinuation<br /><br>b. Dose, dose adjustment and underlying reasons for dose adjustment during 2nd targeted therapy; estimated total dose received for the 2nd-targeted therapy<br /><br>c. Utilization and types of 3rd targeted therapies<br /><br /><br><br>Characterize differences in resource use following initiation of 2nd targeted therapy